Skip to main content

Want a detailed portfolio tracker?

EMBC
NASDAQ
$3.44

Embecta Corp (EMBC)

Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
Website: https://www.embecta.com
68 analysts
Sell
Target: $4 (+16.28%)

Market Cap

$191M

PEG Ratio

0.05

P/E Ratio

1.69

Dividend Yield

18.50%

Price Chart

Valuation
Market Cap$191M
P/E1.69
PEG0.05
P/S0.19
P/B2.61
Profitability
Total Revenue (TTM)$1.04B
Gross Profit (TTM)$646M
EBITDA$312M
Profit Margin-1.8%
Operating Margin15.8%
EPS$1.91
Financial Health
Debt-to-Equity-211.9%
Dividend Yield18.50%
Growth & Risk
Beta (5Y)0.81
Sharpe Ratio-0.84